Saturn V Capital Management
Latest statistics and disclosures from Saturn V Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are AMLX, ALMS, ABVX, PCVX, IMMX, and represent 47.58% of Saturn V Capital Management's stock portfolio.
- Added to shares of these 10 stocks: TRVI (+$20M), SGMT (+$11M), IMMX (+$9.9M), CELC (+$9.2M), ZURA (+$8.0M), VIR (+$7.9M), IRON (+$5.5M), AMLX, CADL, PHVS.
- Started 3 new stock positions in TRVI, VIR, SGMT.
- Reduced shares in these 7 stocks: COGT (-$24M), OVID (-$9.4M), ALMS (-$8.1M), ABVX, MNPR, IVVD, JAZZ.
- Sold out of its position in COGT.
- Saturn V Capital Management was a net buyer of stock by $45M.
- Saturn V Capital Management has $698M in assets under management (AUM), dropping by 26.30%.
- Central Index Key (CIK): 0001964437
Tip: Access up to 7 years of quarterly data
Positions held by Saturn V Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Saturn V Capital Management
Saturn V Capital Management holds 23 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals (AMLX) | 11.9 | $83M | +6% | 4.6M | 17.96 |
|
| Alumis (ALMS) | 11.8 | $82M | -8% | 2.9M | 28.14 |
|
| Abivax Sa Sponsored Ads (ABVX) | 9.9 | $69M | -4% | 519k | 133.26 |
|
| Vaxcyte (PCVX) | 7.1 | $50M | +3% | 853k | 58.13 |
|
| Immix Biopharma (IMMX) | 6.9 | $48M | +26% | 4.7M | 10.31 |
|
| Pharvaris N V (PHVS) | 6.5 | $45M | +9% | 1.3M | 34.58 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 5.6 | $39M | 161k | 240.97 |
|
|
| Celcuity (CELC) | 5.6 | $39M | +31% | 370k | 104.62 |
|
| Disc Medicine (IRON) | 5.5 | $38M | +16% | 525k | 73.14 |
|
| Candel Therapeutics (CADL) | 4.9 | $34M | +14% | 3.3M | 10.30 |
|
| X4 Pharmaceuticals Com New (XFOR) | 4.7 | $33M | +8% | 7.0M | 4.67 |
|
| Monopar Therapeutics Com New (MNPR) | 4.1 | $29M | -9% | 312k | 92.59 |
|
| Dyne Therapeutics (DYN) | 3.4 | $24M | +9% | 1.1M | 22.21 |
|
| Trevi Therapeutics (TRVI) | 2.8 | $20M | NEW | 1.1M | 18.65 |
|
| Zura Bio Class A Ord Shs (ZURA) | 1.8 | $12M | +183% | 2.1M | 5.90 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 1.6 | $11M | NEW | 1.5M | 7.73 |
|
| Oculis Holding Ordinary Shares (OCS) | 1.4 | $9.5M | +32% | 685k | 13.87 |
|
| Inhibikase Therapeutics Com New (IKT) | 1.1 | $7.9M | 3.9M | 2.03 |
|
|
| Vir Biotechnology (VIR) | 1.1 | $7.9M | NEW | 771k | 10.19 |
|
| Adagio Therapeutics (IVVD) | 1.0 | $7.3M | -23% | 8.4M | 0.87 |
|
| Alto Neuroscience Com Shs (ANRO) | 0.7 | $4.8M | +105% | 183k | 26.39 |
|
| Satellos Bioscience (MSLE) | 0.4 | $2.7M | 350k | 7.78 |
|
|
| Ovid Therapeutics (OVID) | 0.3 | $1.8M | -84% | 663k | 2.69 |
|
Past Filings by Saturn V Capital Management
SEC 13F filings are viewable for Saturn V Capital Management going back to 2022
- Saturn V Capital Management 2026 Q2 filed Aug. 14, 2026
- Saturn V Capital Management 2026 Q1 filed May 15, 2026
- Saturn V Capital Management 2025 Q4 filed Feb. 17, 2026
- Saturn V Capital Management 2025 Q3 filed Nov. 14, 2025
- Saturn V Capital Management 2025 Q2 filed Aug. 13, 2025
- Saturn V Capital Management 2025 Q1 filed May 15, 2025
- Saturn V Capital Management 2024 Q4 filed Feb. 14, 2025
- Saturn V Capital Management 2024 Q3 filed Nov. 14, 2024
- Saturn V Capital Management 2024 Q2 filed Aug. 14, 2024
- Saturn V Capital Management 2024 Q1 filed May 15, 2024
- Saturn V Capital Management 2023 Q3 filed Nov. 14, 2023
- Saturn V Capital Management 2023 Q2 filed Aug. 14, 2023
- Saturn V Capital Management 2023 Q1 filed May 15, 2023
- Saturn V Capital Management 2022 Q4 filed Feb. 9, 2023